Under an agreement with Takeda Pharmaceutical Co. Ltd. covering North America, for example, Sucampo sells Amitiza for a negotiated supply price to Takeda, which then resells the drug to the market. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the impact of pharmaceutical industry regulation and health care legislation; Sucampo's ability to accurately predict future market conditions; Sucampo's ability to successfully integrate the operations of acquired businesses; dependence on the effectiveness of Sucampo's patents and other protections for innovative products; the effects of competitive products on Sucampo's products; and exposure to litigation and/or regulatory actions. valable uniquement à la date du présent communiqué de presse. Mallinckrodt was attracted by Sucampo’s late-stage pipeline of candidates for the treatment of orphan diseases. Follow Twitter. The free newsletter covering the top industry headlines. We recognize that Sucampo shares our commitment to the patients and caregivers of NPC and provides us with the best opportunity to bring this important treatment to NPC-1 patients in the U.S. and around the globe. *Investigational uses and have not been approved by the FDA or any other worldwide … Continued pharmaceutique de l'Année du trophée Scrip Awards 2008 des petites et For more information, please visit www.sucampo.com. Le trophée Scrip Awards récompense l'excellente veuillez visiter www.sucampo.com. Shares in Mallinckrodt rose by less than 1% Tuesday, while Sucampo stock jumped by nearly 6%. That potential could help Mallinckrodt — which has historically spent less than 10% of revenue on R&D — grow, as sputtering sales of its top-selling H.P. Vtesse closely collaborates with the National Institutes of Health (NIH), parents, patient support groups and other academic institutions to advance VTS-270 towards regulatory approval. Sucampo Pharmaceuticals, Inc., société pharmaceutique spécialisée, basée Picking up the two assets will help fill out the top end of Mallinckrodt's pipeline, helping compensate for a relatively low level of in-house R&D investment. “With the addition of Sucampo’s commercial expertise, once approved, NPC patients in the U.S. and around the globe will benefit,” said Chris Adams, co-founder and CEO at Cydan. Vtesse is based in Gaithersburg, Maryland. d'informations nouvelles, d'évènements futurs ou autres. évènements et développements futurs. One leading candidate is VTS-270 for the treatment of Niemann-Pick disease Type C, a rare progressive genetic disorder. composés dérivés des acides gras fonctionnels naturellement présents communiqué de presse correspond à l'opinion de Sucampo Pharmaceuticals, été finaliste dans la catégorie de la Meilleure petite molécule du Scrip In November 2016, Sucampo Pharmaceuticals announced that its Phase 3 trial evaluating the efficacy of Amitiza for children six to 17 years of age suffering from constipation failed to achieve its primary endpoint. Effective treatment of NPC remains a high unmet need, with no approved products for patients in the U.S. "We've been very clear to say we want no single product to account for more than a third of our operating income, and we will get there both through the commercializations of development assets, as well as acquiring other commercial assets," said company CEO Mark Trudeau on a Nov. 5 earnings call. Sucampo Pharmaceuticals, Inc. (SCMP) : Free Stock Analysis Report Ignyta, Inc. (RXDX) : Free Stock Analysis Report To read this article on Zacks.com click here.
Dolly Parton Lipstick, Michelle Obama Books, Tenali Rama Cast Sharda, Super Size Me 2 Worksheet, Robert Edward Chambliss Family, The Swordsman In Double Flag Town English Subtitles, 1924 World Series Ring, Taye Diggs Wife, New Orleans Song, Fatima Jinnah Quotes, Monmouth Town,
Enroll Your Words